Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

MAB5466

Sigma-Aldrich

Anti-Bestrophin Antibody

Chemicon®, from mouse

Sinonimo/i:

Anti-Anti-ARB, Anti-Anti-BEST, Anti-Anti-BMD, Anti-Anti-Best1V1Delta2, Anti-Anti-RP50, Anti-Anti-TU15B, Anti-Anti-VMD2

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Origine biologica

mouse

Livello qualitativo

100

Forma dell’anticorpo

purified immunoglobulin

Tipo di anticorpo

primary antibodies

Clone

monoclonal

Reattività contro le specie

monkey, pig, mouse, bovine, human

Produttore/marchio commerciale

Chemicon®

tecniche

immunohistochemistry: suitable
western blot: suitable

Isotipo

IgG

N° accesso NCBI

NM_004183.2

N° accesso UniProt

O76090

Condizioni di spedizione

dry ice

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... BEST1(7439)

Specificità

Reacts with bestrophin.

Immunogeno

Recombinant human bestrophin protein.

Applicazioni

Detect Bestrophin using this Anti-Bestrophin Antibody validated for use in WB, IH.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Western blot: 5 μg/mL of this antibody detected Bestrophin in bovine retina cell lysate.

Immunohistochemistry (Paraffin) Analysis: A 1:20 dilution from a representative lot detected Bestrophin in mouse retina tissue sections.

Optimal working dilutions must be determined by end user.

Stato fisico

Format: Purified
Purified immunoglobulin. Liquid in PBS containing 0.08% sodium azide.

Stoccaggio e stabilità

Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.

Altre note

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Note legali

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Motore di ricerca dei prodotti.

Raccomandato

N° Catalogo
Descrizione
Determinazione del prezzo

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Sandra Petrus-Reurer et al.
Stem cells translational medicine, 9(8), 936-953 (2020-04-23)
As pluripotent stem cell (PSC)-based reparative cell therapies are reaching the bedside, there is a growing need for the standardization of studies concerning safety of the derived products. Clinical trials using these promising strategies are in development, and treatment for
Teisha J Rowland et al.
Journal of tissue engineering and regenerative medicine, 7(8), 642-653 (2012-04-20)
A potential application of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) is the generation of retinal pigmented epithelium (RPE) to treat age-related macular degeneration (AMD), a common but incurable retinal disease. RPE cells derived from hESCs
Altered zinc homeostasis in a primary cell culture model of the retinal pigment epithelium.
??lvarez-Barrios, et al.
Frontiers in nutrition, 10, 1124987-1124987 (2023)
Divya Sinha et al.
American journal of human genetics, 107(2), 278-292 (2020-07-25)
Dominantly inherited disorders are not typically considered to be therapeutic candidates for gene augmentation. Here, we utilized induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) to test the potential of gene augmentation to treat Best disease, a dominant macular dystrophy
Alvaro Plaza Reyes et al.
Nature communications, 11(1), 1609-1609 (2020-04-02)
In vitro differentiation of human pluripotent stem cells into functional retinal pigment epithelial (RPE) cells provides a potentially unlimited source for cell based reparative therapy of age-related macular degeneration. Although the inherent pigmentation of the RPE cells have been useful
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.